Literature DB >> 21279986

Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?

Steven L Teitelbaum1, Margaret P Seton, Kenneth G Saag.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21279986      PMCID： PMC3069536          DOI： 10.1002/art.30135

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  39 in total

Review 1.  Bone histomorphometry in glucocorticoid-induced osteoporosis.

Authors:  D W Dempster
Journal:  J Bone Miner Res       Date:  1989-04       Impact factor: 6.741

2.  Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

Authors:  Wei Yao; Zhiqiang Cheng; Cheryl Busse; Aaron Pham; Mary C Nakamura; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-06

Review 3.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

Authors: 
Journal:  Arthritis Rheum       Date:  2001-07

4.  Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography.

Authors:  P Rüegsegger; T C Medici; M Anliker
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.

Authors:  Robert S Weinstein; Jin-Ran Chen; Cara C Powers; Scott A Stewart; Reid D Landes; Teresita Bellido; Robert L Jilka; A Michael Parfitt; Stavros C Manolagas
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

6.  Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

Authors:  Philip N Sambrook; Mark Kotowicz; Peter Nash; Colin B Styles; Vasi Naganathan; Kathy N Henderson-Briffa; John A Eisman; Geoff C Nicholson
Journal:  J Bone Miner Res       Date:  2003-05       Impact factor: 6.741

7.  Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Authors:  Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

8.  Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.

Authors:  T P Van Staa; R F Laan; I P Barton; S Cohen; D M Reid; C Cooper
Journal:  Arthritis Rheum       Date:  2003-11

9.  Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis.

Authors:  A M Parfitt; A R Villanueva; J Foldes; D S Rao
Journal:  J Bone Miner Res       Date:  1995-03       Impact factor: 6.741

10.  The course of biochemical parameters of bone turnover during treatment with corticosteroids.

Authors:  M F Prummel; W M Wiersinga; P Lips; G T Sanders; H P Sauerwein
Journal:  J Clin Endocrinol Metab       Date:  1991-02       Impact factor: 5.958
View more
  17 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  Bone: the conundrum of glucocorticoid-induced osteoporosis.

Authors:  Steven L Teitelbaum
Journal:  Nat Rev Endocrinol       Date:  2012-06-12       Impact factor: 43.330

3.  High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.

Authors:  H Sato; N Kondo; T Nakatsue; Y Wada; J Fujisawa; J J Kazama; T Kuroda; Y Suzuki; M Nakano; N Endo; I Narita
Journal:  Osteoporos Int       Date:  2017-04-13       Impact factor: 4.507

4.  The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.

Authors:  H Sato; N Kondo; Y Wada; T Nakatsue; S Iguchi; J Fujisawa; J J Kazama; T Kuroda; M Nakano; N Endo; I Narita
Journal:  Osteoporos Int       Date:  2015-10-30       Impact factor: 4.507

Review 5.  Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

Authors:  Hennie G Raterman; Irene E M Bultink; Willem F Lems
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

6.  Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.

Authors:  J H Koh; J P Myong; J Yoo; Y-W Lim; J Lee; S-K Kwok; S-H Park; J H Ju
Journal:  Osteoporos Int       Date:  2017-07-27       Impact factor: 4.507

Review 7.  Bone health issues in sarcoidosis.

Authors:  Nadera J Sweiss; Elyse E Lower; Peter Korsten; Timothy B Niewold; Murray J Favus; Robert P Baughman
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 8.  Prevention and treatment of bone changes associated with exposure to glucocorticoids.

Authors:  Amy H Warriner; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

9.  Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.

Authors:  Jianrong Zhao; Yingbin Li; Hao Zhang; Dongying Shi; Qingnan Li; Yan Meng; Li Zuo
Journal:  J Bone Miner Metab       Date:  2019-01-31       Impact factor: 2.626

Review 10.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.